NEWS
GE Water to be renamed Suez Water Technologies & Solutions
W
hen French utility Suez completes its acquisition of GE Water & Process Technologies from General Electric Co, it will combine the business with Suez industrial water activities to create Suez Water Technologies & Solutions (Suez WTS) (see Filtration Industry Analyst, March 2017). The Suez WTS business will be headed by Heiner Markhoff, president and CEO of GE Water & Process Technologies. The financing has been completed and the acquisition is expected to close by the end of September 2017. The deal will strengthen Suez’s position in industrial water, particularly in the US and emerging markets. For further information, visit www.gewater.com and www.suez-environnement.fr
“We are pleased to welcome these investors to Fluence,” said Fluence executive chairman Richard Irving. “The global water sector is an estimated US$700 billion annual market and we are delighted that one of the world’s largest and most respected financial institutions has put their confidence in Fluence as a promising growth company in the sector. We hope this initial investment will be a stepping stone for future support from this, and other high-quality funds.” Henry Charrabé, managing director and CEO of Fluence, said: “This strategic investment provides Fluence with additional flexibility over the coming year, to target, and rapidly deliver on further growth opportunities as they materialize.” Fluence was established with the vision of becoming the leading global provider of fast-to-deploy decentralized and packaged water and wastewater treatment solutions. The company currently provides products and services for water treatment, wastewater treatment, desalination, waste-to-energy and water reuse and recovery in markets including municipal, commercial, industrial, mining, oil & gas, power, food and beverage. For further information, visit www.fluencecorp.com
Fluence secures strategic investment from US-based institutional investor
F
luence Corp has announced a US$10 million strategic investment in the company by a large US-based institutional investor, while a second investor will also participate in the private placement, bringing the total amount raised to US$11 million. In a statement, Fluence said that the private placement will help satisfy a number of its stated objectives “including a steady transformation of the company’s share register towards a more global investor base, attracting high-quality US-based funds in anticipation of a future potential listing on a US stock exchange and providing working capital to fund new growth opportunities.” Fluence was formed in July 2017 with the merger of Emefcy Group Ltd and RWL Water LLC (see Filtration Industry Analyst, May and July 2017). Headquartered in New York, Fluence is listed on the Australian Securities Exchange (ASX). 16
Filtration Industry Analyst
Mann+Hummel opens office in Iran
G
erman filtration specialist Mann+Hummel now has its own representation in Iran with the opening of an office in Tehran. The new Iranian office will support Mann+Hummel customers in the automotive aftermarket and industrial sectors. Employees will help local distributors at trade fairs and provide product training. They will also study the market and contact potential new customers. “Iran is already the biggest automotive aftermarket in the Middle East and is attractive due to its numerous local vehicle and machine manufacturers,” said Josef Parzhuber, Mann+Hummel’s president and general manager Automotive Aftermarket. “The Iranian market has enormous potential and also offers Mann+Hummel opportunities for growth with automotive OEMs and with air and water filtration,” added Parzhuber.
Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail:
[email protected] Production Support Manager: Lin Lucas E-mail:
[email protected] Executive Publisher: Laney Priestley Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received.
More information: www.elsevier.com/journals/institutional/filtrationindustry-analyst/1365-6937 Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email:
[email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) LImited 12976 The content of this newsletter is compiled from a variety of sources including press releases.
For further information, visit www.mann-hummel.com August 2017